# Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

> **NCT01372644** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 15 (actual)

## Conditions studied

- Atypical Ductal Breast Hyperplasia
- Lobular Carcinoma in Situ (LCIS)
- Atypical Lobular Hyperplasia (ALH) of Breast

## Interventions

- **DRUG:** SOM 230 / Pasireotide

## Key facts

- **NCT ID:** NCT01372644
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-12
- **Final completion:** 2013-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2016-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01372644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01372644, "Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01372644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*